Professor of Emerging Viruses
Carroll Group: High Consequence Emerging Viruses Group
HOST-PATHOGEN INTERACTIONS OF HIGH CONSEQUENCE EMERGING VIRUSES
Our work centres around high consequence emerging viral infections. Currently, our focus is on Ebola, Lassa fever and SARS-CoV-2. We are interested in host-pathogen interactions, development of anti-virals and recently we have been looking at the IgG response following SARS-CoV-2 infection and/or vaccination in humans and animal models. To further support this work we are using a live virus neutralisation, multiplex immunoassays and novel ACE2 inhibition assay to inform on the ability of serum to neutralise SARS-CoV-2 variants of concern (VOC). We are also interested in the innate response to viral infection, particularly activation and/or evasion of the complement system
Direct enhancement of viral neutralising antibody potency by the complement system: a largely forgotten phenomenon.
Mellors J. and Carroll M., (2024), Cellular and molecular life sciences : CMLS, 81
Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents.
Ratcliffe H. et al, (2023), iScience, 26
Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients.
Murray SM. et al, (2023), Journal of hepatology
A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2.
Wilkinson T. et al, (2023), ERJ open research, 9, 249 - 2023
CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH study.
Neale I. et al, (2023), mBio